Thomas Schlake
Paul Ehrlich Str. 15
Tuebingen, BW 72076, Germany
Tuebingen, BW 72076, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Sequence-Optimized mRNA Vaccines Against Infectious Disease.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: May 30, 2024
mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5.
Journal: Molecular therapy. Methods & clinical development
Published: September 02, 2019
mRNA: A Novel Avenue to Antibody Therapy?
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 14, 2018
mRNA as novel technology for passive immunotherapy.
Journal: Cellular and molecular life sciences : CMLS
Published: June 18, 2018
mRNA mediates passive vaccination against infectious agents, toxins, and tumors.
Journal: EMBO molecular medicine
Published: August 11, 2017
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: December 18, 2016
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 30, 2015
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.
Journal: Human vaccines & immunotherapeutics
Published: August 08, 2013
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.
Journal: Nature biotechnology
Published: July 02, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026